E2086

DRUG7 trials

Sponsors

Eisai Limited, Eisai Inc.

Conditions

Healthy VolunteersNarcolepsyNarcolepsy Type 1 (NT1)

Phase 1

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

CompletedNCT05745207

Eisai Inc.Healthy Volunteers

Start: 2023-02-20End: 2024-01-18Updated: 2024-10-02

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

CompletedNCT06462404

Eisai Inc.Narcolepsy Type 1 (NT1)

Start: 2024-06-20End: 2025-03-17Updated: 2025-06-04

A Study of E2086 in Healthy Adult Participants

CompletedNCT06481488

Eisai Inc.Healthy Volunteers

Start: 2024-06-25End: 2024-12-13Updated: 2025-01-16

A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants

CompletedNCT07308236

Eisai Inc.Healthy Volunteers

Start: 2025-12-31End: 2026-06-12Updated: 2026-08-21

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

Not yet recruitingNCT07766369

Eisai Inc.Healthy Volunteers

Start: 2026-08-12End: 2026-11-12Target: 93Updated: 2026-08-14

Phase 2

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

RecruitingNCT07493265

Eisai Inc.Narcolepsy

Start: 2026-03-26End: 2027-03-01Target: 64Updated: 2026-05-14

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

Not yet recruitingCTIS2025-523503-30-00

Eisai LimitedNarcolepsy

Target: 51Updated: 2026-07-09